Tesamorelin for Belly-Fat Progress | Visceral Fat, Label, Cost

Tesamorelin is the kind of peptide you look at when waistline progress matters more than scale drama. It is built for visceral-fat reduction, not for the broad appetite shutdown you get from GLP-1 drugs, so the question is less “how much weight will I lose?” and more “does this match the kind of change I actually want?”

Where tesamorelin sits in a weight-loss plan

Tesamorelin earns attention because it goes after deep abdominal fat, the kind that sits around your organs and changes the way your midsection looks and feels. That makes it appealing if you want a tighter waist and better body composition, but it also means you should not expect the same quick, full-body drop you might associate with semaglutide or tirzepatide.

The FDA framing is narrow on purpose. EGRIFTA WR is indicated for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and the label says it is not indicated for weight loss management. In plain English: this is a targeted tool for a specific fat pattern, not a general obesity drug.

That narrow lane is why tesamorelin can make sense for someone who cares about midsection change, but not for someone chasing broad, fast scale loss. It is a growth-hormone-releasing hormone analog, which means it nudges your body to make more of its own growth hormone; that matters because the practical goal is body recomposition, not appetite suppression.

What the research and FDA label really support

The strongest evidence comes from HIV lipodystrophy studies, where tesamorelin reduced visceral adipose tissue, the exact fat compartment the drug is meant to target. In the randomized placebo-controlled 2010 trial, participants saw meaningful abdominal-fat reduction, and the more recent 2024 integrase-inhibitor study kept the conversation focused on visceral-fat change rather than generic weight loss.

That distinction matters because the label and the trial design line up. The approved EGRIFTA WR dose is 1.28 mg once daily, given by subcutaneous injection, and the label says EGRIFTA WR and EGRIFTA SV are not substitutable. So if you're comparing products, the version and the dose schedule are part of the decision, not a small technicality. The routine is also more hands-on than many weight-loss injectables. A 11.6 mg vial is mixed with 1.3 mL of diluent to make 7 doses, and the 28-day kit is built around four single-patient-use vials plus supplies.

That means you're planning around weekly vial turnover, not grabbing a simple prefilled pen and moving on. The practical tradeoffs: access, routine, and expectations: This is where tesamorelin looks different from the GLP-1 class. Access is prescription-only, and it is usually more niche because the FDA-approved use is so specific. If your main goal is visible belly-fat progress, that narrowness can be a plus; if you want a widely covered, broadly prescribed weight-loss drug, it is a constraint.

Cost also deserves a straight answer. Public pricing for Egrifta is not in the same league as a routine retail copay; Drugs.com’s price guide has historically shown a cash price in the several-thousand-dollar range for a month of treatment, which is why insurance status, specialty-pharmacy routing, and refill timing matter so much. The manufacturer product page also makes clear this is a branded, specialized therapy, not a casual add-on. The cleanest way to think about tesamorelin is this: it can support a more refined midsection result, but it asks for a daily injection routine, a prescription pathway, and a realistic view of what the data actually measured. The upside is specificity. The tradeoff is that specificity is exactly why it does not behave like a general weight-loss shortcut.